Any current/future new fundraising through debt or equity?

No new debt has been raised for the recent acquisition of OMERAS; it was entirely financed through internal accruals. The acquisition cost of €2.75 million (about Rs. 27.5 crores) does not stretch the balance sheet or add to debt. The broad capital allocation strategy continues to prioritize keeping debt within reasonable levels and pursuing debt reduction at the consolidated level. There is no indication of immediate plans for fresh fundraising through debt or equity mentioned in the call. The company focuses on internal capital generation and prudent capital management for acquisitio

Any current/future capex/capital investment/strategic investment?

No major CAPEX required from a capacity point of view as current installed capacity utilization at OMERAS is below 50% (Page 17). Incremental CAPEX might be needed for balancing equipment and maintenance but no immediate major CAPEX planned (Page 8). Land available for future expansion (~21,000 sq. meters), but no immediate plans to build more capacity (Page 8). Expansion to be organically leveraged without significant fresh capital outlay (Page 17). Acquisition financed entirely from internal accruals; no additional debt taken (Page 16). Strategic focus on organic growth and leveraging techno

Future growth expectations in sales/revenue/volumes?

HLE Glascoat expects consolidated topline growth of 16%-18% annually, potentially closer to 20% based on current order book (Page 12). OMERAS acquisition will add incremental growth over this base but will not be included in the 20% calculation (Page 12). For OMERAS, 12-month revenues are expected to be between €20 million and €25 million in FY '27, as FY '26 will reflect only partial consolidation and transition (Page 11-12). Capacity utilization at OMERAS is currently below 50%, indicating scope for growth without major CAPEX (Page 8). Execution timelines for projects vary from 5-6 months fo

Future growth expectations in earnings/operating earnings/profits/EPS?

HLE Glascoat expects consolidated topline growth of 16%-18% annually, potentially closer to 20% considering the current order book (Page 12). OMERAS acquisition is anticipated to contribute additional growth beyond the existing business, with FY '27 revenues expected between €20-25 million (Pages 11-12). EBITDA margins for OMERAS are targeted in the double-digit mid-teens range, aligning with HLE's European business profitability (Page 15). The overall operating margin across businesses aims for mid to high teens, with Kinam exceeding 20% operating margin (Page 12). The acquisition is expected

Current/ Expected Orderbook/ Pending Orders?

Current order book of OMERAS is roughly around €7 million (page 7). There is an inquiry pipeline of about €28 million under negotiation, which will be executed over 12-18 months (page 7). The order book is partially executed already (page 6). Orders include a mix of tanks and facades; biogas is still under discussion and not included in these numbers (page 7). Orders taken exclude any with potential liability related to delayed execution or penalty clauses (page 6). The order book and pipeline provide a healthy base for expected profitable business turnaround within 3-4 quarters (page 8).

IN US

Sale is live|00:00:00left today

HLE Glascoat LtdQ2 FY25Industrial Manufacturing

HLE Glascoat Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹381P/E: 41.4Market Cap: ₹2.2K CrSector: Industrial Manufacturing

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Yes

Capex

1 of 5 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→HLE Glascoat expects consolidated topline growth of 16%-18% annually, potentially closer to 20% based on current order book (Page 12).
→OMERAS acquisition will add incremental growth over this base but will not be included in the 20% calculation (Page 12).
→For OMERAS, 12-month revenues are expected to be between €20 million and €25 million in FY '27, as FY '26 will reflect only partial consolidation and transition (Page 11-12).
→Capacity utilization at OMERAS is currently below 50%, indicating scope for growth without major CAPEX (Page 8).
→Execution timelines for projects vary from 5-6 months for smaller orders to over 2 years for larger orders (Page 15).
→Pharmaceutical segment has shown double-digit growth and is expected to continue performing well in the next 1-2 years (Page 12).
→Overall, mid to high teens EBITDA margins and growth driven by synergies and expanding markets are targeted (Page 12).

Margin guidance

Category 3

→HLE Glascoat expects consolidated topline growth of 16%-18% annually, potentially closer to 20% considering the current order book (Page 12).
→OMERAS acquisition is anticipated to contribute additional growth beyond the existing business, with FY '27 revenues expected between €20-25 million (Pages 11-12).
→EBITDA margins for OMERAS are targeted in the double-digit mid-teens range, aligning with HLE's European business profitability (Page 15).
→The overall operating margin across businesses aims for mid to high teens, with Kinam exceeding 20% operating margin (Page 12).
→The acquisition is expected to be EPS accretive within 2 to 3 quarters post-integration (Page 15).
→ROE and ROCE should improve positively due to acquiring OMERAS below book value; no business multiple premium was paid (Page 15).

3 more insights locked — sign up free to unlock

Fundraise plans

→No new debt has been raised for the recent acquisition of OMERAS; it was entirely financed through internal accruals.
→The acquisition cost of €2.75 million (about Rs. 27.5 crores) does not stretch the balance sheet or add to debt.
→The broad capital allocation strategy continues to prioritize keeping debt within reasonable levels and pursuing debt reduction at the consolidated level.
→There is no indication of immediate plans for fresh fundraising through debt or equity mentioned in the call.
→The company focuses on internal capital generation and prudent capital management for acquisitions and growth.

Order book

Yes

→Current order book of OMERAS is roughly around €7 million (page 7).
→There is an inquiry pipeline of about €28 million under negotiation, which will be executed over 12-18 months (page 7).
→The order book is partially executed already (page 6).
→Orders include a mix of tanks and facades; biogas is still under discussion and not included in these numbers (page 7).
→Orders taken exclude any with potential liability related to delayed execution or penalty clauses (page 6).
→The order book and pipeline provide a healthy base for expected profitable business turnaround within 3-4 quarters (page 8).

Capex plans

→No major CAPEX required from a capacity point of view as current installed capacity utilization at OMERAS is below 50% (Page 17).
→Incremental CAPEX might be needed for balancing equipment and maintenance but no immediate major CAPEX planned (Page 8).
→Land available for future expansion (~21,000 sq. meters), but no immediate plans to build more capacity (Page 8).
→Expansion to be organically leveraged without significant fresh capital outlay (Page 17).
→Acquisition financed entirely from internal accruals; no additional debt taken (Page 16).
→Strategic focus on organic growth and leveraging technology, with no present plan for aggressive inorganic investments beyond the current strategy (Pages 11, 13).
→No CAPEX planned for turning the acquired business around; expected turnaround within 3-4 quarters (Page 8).

How does HLE Glascoat Ltd rank vs peers in Industrial Manufacturing?

Pro feature

1HLE Glascoat Ltd

Rev 3Mar 3

See full Industrial Manufacturing sector rankings

Want more stocks like HLE Glascoat Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio